Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1154117 | 0.98 | CYP3A4 (0.35) | CYP3A4CYP2C9CYP2C19MMETSHR | |
| SCHEMBL1153699 | 0.95 | CYP3A4 (0.35) | CYP3A4CYP2C9CYP2C19MMETSHR | |
| SCHEMBL1152983 | 0.92 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1152431 | 0.87 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19MMECETP | |
| SCHEMBL1154028 | 0.85 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP2C19MME | |
| SCHEMBL1153174 | 0.85 | MME (0.31) | MMELMNA | |
| SCHEMBL1154254 | 0.84 | TSHR (0.31) | CYP3A4MMETSHRLMNANFKB1 | |
| SCHEMBL1154409 | 0.83 | MME (0.32) | CYP3A4CYP2C9CYP2C19MME | |
| SCHEMBL1154005 | 0.82 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP2C19MME | |
| SCHEMBL1153262 | 0.82 | TSHR (0.31) | CYP3A4MMETSHRLMNANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943799-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
| US-7842839-B2 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1698617-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENE BISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112201-A1 | Method for producing optically active cycloalkylidenebisoxazoline compound and intermediate thereof | CYP3A7, GRK7, CYP2A7 | CYP3A4 29/4885CYP2C9 24/4885CYP2C19 34/4885 |
| US-20110046415-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOALKYLIDENEBISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | CYP3A7, GRK7, CYP2A7 | CYP3A4 29/4885CYP2C9 24/4885CYP2C19 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.